The exclusive sales agreement between Mundipharma and Biosolution Co. Ltd was announced on 7th January 2020.
Manufacturer and distributor of pharmaceuticals, Biosolution Co. Ltd has signed an exclusive sales agreement with Mundipharma to market and distribute its fourth-generation autologous chondrocyte implantation product, CartiLife.
This is the second deal between Mundipharma and Biosolution Co., Ltd following the exclusive sales agreement for the allogeneic keratinocyte cell therapy product, KeraHeal-Allo™, which was announced in May 2016.
“We are delighted to extend our relationship with Biosolution to include CartiLife®, which adds to our portfolio of products for orthopedic care,” said Mundipharma’s CEO, Raman Singh. “It is also another example of our support for innovative treatments developed in Asia and our ability to increase their market presence.”
CartiLife® is an autologous cartilage-derived chondrocyte cell therapy for the treatment of cartilage defects (ICRS grade 3 or 4). Its key benefits include significantly reduced risk of host-immune rejection due to its autologous nature, direct restoration of hyaline cartilage, and a less invasive surgery followed by shorter recovery times compared to alternative, comparable therapies.
Under the agreement, Mundipharma obtains the rights to market and distribute CartiLife® in South Korea. [APBN]